pFUSE-hIgG1-Fc2

Plasmid designed for the construction of Fc-Fusion proteins

Catalog # pfuse-hg1fc2

For research use only

Version # 06G05-MT

PRODUCT INFORMATION
Content: - 20 g of pFUSE-hIgG1-Fc2(IL2ss) plasmid provided as lyophilized DNA - 4 pouches of E. coli Fast-Media Zeo (2 TB and 2 Agar) Storage and Stability: - Product is shipped at room temperature. - Lyophilized DNA should be stored at -20C and is stable 3 months. - Resuspended DNA should be stored at -20C and is stable up to 1 year. - Store E. coli Fast-Media Zeo at room temperature. Fast-Media pouches are stable 18 months when stored properly. Quality control: - Plasmid construct has been confirmed by restriction analysis and sequencing. - Plasmid DNA was purified by ion exchange chromatography and lyophilized.

PLASMID FEATURES
hIgG1-Fc (human): The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently. Human IgG1 dispays high ADCC and CDC, and is the most suitable for therapeutic use against pathogens and cancer cells. hEF1-HTLV prom is a composite promoter comprising the Elongation Factor-1! (EF-1!) core promoter1 and the R segment and part of the U5 sequence (R-U5) of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat2. The EF-1! promoter exhibits a strong activity and yields long lasting expression of a transgene in vivo. The R-U5 has been coupled to the EF-1! core promoter to enhance stability of RNA. IL2 ss: The IL2 signal sequence contains 20 amino acids and share common characteristics with signal peptides of other secretory proteins. The intracellular cleavage of the IL2 signal peptide occurs after Ser20 and leads to the secretion of the antigenic protein. MCS: The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning. SV40 pAn: the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA3. ori: a minimal E. coli origin of replication to limit vector size, but with the same activity as the longer Ori. CMV enh / hFerL prom: This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin-resistance gene in mammalian cells. EM2KC is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in E. coli. EM2KC is located within an intron and is spliced out in mammalian cells. Zeo: Resistance to Zeocin is conferred by the Sh ble gene from Streptoalloteichus hindustanus The same resistance gene confers selection in both mammalian cells and E. coli. Glo pAn: The human beta-globin 3UTR and polyadenylation sequence allows efficient arrest of the transgene transcription4.
1. Kim DW et al. 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23. 2. Takebe Y. et al. 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72. 3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58. 4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

GENERAL PRODUCT USE

pFUSE-Fc is a family of plasmid developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG). pFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the g/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells, cells that are commonly used in protein purification systems. pFUSE-Fc2 (IL2ss) plasmids allow the secretion of Fc-Fusion proteins. They contain the IL2 signal sequence (IL2ss) for the generation of Fc-Fusion proteins derived from proteins that are not naturally secreted. As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pFUSE-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting. Fc-Fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography. InvivoGen provides pFUSE-Fc vectors featuring Fc regions from different species and isotypes. In humans, there are four isotypes: IgG1, IgG2, IgG3 and IgG4. The Fc region mediates eff e c t o r functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IgG isoforms exert different levels of effector functions increasing in the order of IgG4<IgG2<IgG1!IgG3.

TECHNICAL SUPPORT Toll free (US): 888-457-5873 Outside US: (+1) 858-457-5873 E-mail: info@invivogen.com Website: www.invivogen.com

3950 Sorrento Valley Blvd. Suite 100 San Diego, CA 92121 - USA

METHODS
Plasmid resuspension: Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 g/l, resuspend the DNA in 20 l of sterile H2O. Store resuspended plasmid at -20C. Selection of bacteria with E. coli Fast-Media Fast-Media is a fast and convenient way to prepare liquid and solid media for bacterial culture by using only a microwave. Fast-Media is a TB (liquid) or LB (solid) based medium that already contains the antibiotic. Fast-Media Zeo is available separately: #fas-zn-l (liquid), #fas-zn-s (agar). 1- Pour the contents of a Fast-Media pouch into a clean borosilicate glass bottle or flask. 2- Add 200 ml of distilled water to the flask 3- Heat in a microwave on MEDIUM power setting (about 400Watts), until bubbles start appearing (approximately 3 minutes). Do not heat a closed container. Do not autoclave Fast-Media. 4- Swirl gently to mix the preparation. Be careful, the bottle and media are hot, use heatproof pads or gloves and care when handling. 5- Reheat the media for 30 seconds and gently swirl again. Repeat as necessary to completely dissolve the powder into solution. But be careful to avoid overboiling and volume loss. 6- Let agar medium cool to 45C before pouring plates. Let liquid media cool to 37C before seeding bacteria. Note: Do not reheat solidified Fast-Media as the antibiotic will be permanently destroyed by the procedure.

RELATED PRODUCTS
Product Zeocin Fast-Media Zeo TB Fast-Media Zeo Agar

Catalog Code ant-zn-1 fas-zn-l fas-zn-s

TECHNICAL SUPPORT Toll free (US): 888-457-5873 Outside US: (+1) 858-457-5873 E-mail: info@invivogen.com Website: www.invivogen.com

3950 Sorrento Valley Blvd. Suite 100 San Diego, CA 92121 - USA

SgfI (11)

NotI (4031)
SwaI (4023) PacI (4015)

PvuII (242)
HindIII (246)

hEF1-HTLV prom

EcoRI (626) EcoRV (634) NcoI (640) BglII (648)

Ori
BspLU11I (3281)
PacI (3275)

IL2ss

BspHI (745)

SdaI (3268)
PstI (3268)

hIgG1 Fc

pFUSE-hIgG1-Fc2
CMV enh
(4194 bp)

SmaI (1056)

XmnI (1257)

SpeI (2852) BspEI (2745)

hFerL

SV40 pAn

NheI (1340) HpaI (1480)

AseI (1577) XmnI (1578)

EM2KC Zeo

Glo pAn

HindIII (2587) PstI (2483) AseI (2461) SmaI (2275)

SwaI (1834)

110

1 GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA 101 GAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC HindIII (246) 201 GTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAG GGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCC 301 GCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC 401 GGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTT 501 TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATGTACAGGATGCAACTCCTGTCTTGCA 1 Me t T y r A r gMe t G l nLeuLeuSe r Cys I

SgfI (11)

PvuII (242)

601 TTGCACTAAGTCTTGCACTTGTCACGAATTCGATATCGGCCATGGTTAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGG 1 As pLy s Th r Hi s Th r Cys P r oP r oCys P r oA l a P r oG l uLeuLeuG l 1 0 l eA l a LeuSe r LeuA l a LeuVa l Th r A s nSe r 701 16 801 50 901 83 1001 116 1101 150 1201 183 GGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA yG l y P r oSe r Va l Ph eLeuPh eP r oP r oLy s P r oLysAs pTh r LeuMe t I l eSe r A r gTh r P r oG l uVa l Th r Cys Va l Va l Va l As pVa l Se r Hi s G l u GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGG As pP r oG l uVa l Ly s Ph eAs nT r pT y r Va l As pG l yVa l G l uVa l Hi sAs nA l a Ly s Th r Ly s P r oAr gG l uG l uG l nTyrAs nSe r Th r T y r A r gVa l V TCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCAT a l Se r Va l LeuTh r Va l LeuHi s G l nAs pT r pLeuAs nG l yL y s G l uT y r Ly s Cys Ly s Va l Se r A s nLysA l a LeuP r oA l a P r o I l eG l uLy s Th r I l SmaI (1056) CTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAG GAGA TGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC eSe r LysA l a Ly s G l yG l nP r oAr gG l uP r oG l nVa l T y r Th r LeuP r oP r oSe r A r gG l uG l uMe t Th r LysAs nG l nVa l Se r LeuTh r Cys LeuVa l AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCT Ly s G l yPh eT y r P r oSe r A s p I l eA l a Va l G l uT r pG l uSe r A s nG l yG l nP r oG l uAs nAs nT y r Ly s Th r Th r P r oP r oVa l LeuAs pSe r A s pG l y S XmnI (1257) CCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTA er Ph ePh eLeuT y r Se r Ly s LeuTh r Va l As pLy s Se r A r gT r pG l nG l nG l yAs nVa l Ph eSe r Cys Se r Va l Me t Hi s G l uA l a LeuHi sAs nHi s T y

EcoRV (634) BglII (648) EcoRI (626) NcoI (640)

BspHI (745)

1301 CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC 216 r Th r G l nLy s Se r LeuSe r LeuSe r P r oG l yL y s 1401 AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCA AseI (1577) XmnI (1578) 1501 TTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCA 1601 AAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTG 1701 CAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCAC SwaI (1834) 1801 ATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTC 1901 ATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTG 125 As pG l n 2001 CTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAG 122 G l uG l uA l a Va l Ph eHi s Va l CysAs nG l yA l a P r oAs pAr gLeuA l a Ph eG l uAr gG l y T r pP r oG l nG l uG l y I l eG l uTh r Me tA l a P r oG l ySe r A 2101 GCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCT 8 8 l aAs pAr gPh eAs nTh r Se r Va l Va l G l uSe r T r pG l uA l a T y r LeuG l uAs pLeuG l yA r gVa l T r pVa l T r pA l a LeuTh r A s nAs pP r oVa l Va l G l SmaI (2275) 2201 GGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCA 5 5 nAs pG l nVa l A l a Se r I l ePh eLeuTh r Va l As pAs pAr gVa l Va l G l yA l a Ph eAs pAs pG l uVa l Ph eAs pAr gSe r Ph eG l yL euAr gAs pTh r T r p 2301 GAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaaga 2 2 Ph eG l uVa l A l a G l yA l a Va l As pAr gA l a Th r LeuVa l P r oVa l A l a Se r Th r LeuLysA l a Me t AseI (2461) PstI (2483) 2401 aggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccact HindIII (2587) 2501 tttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGA 2601 CCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCA

NheI (1340)

HpaI (1480)

2701 ATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGC

BspEI (2745)

2801 CTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAA 2901 ATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGT 3001 AGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGA 3101 TGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACG

SpeI (2852)

PacI (3275) PstI (3268) 3201 TCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTT AATTAAGAACATGTGAGCAAAAGGCCAG 3301 CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGT 3401 GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTC 3501 CGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAT AGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC 3601 GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG 3701 GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTG 3801 CGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG 3901 CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGG PacI (4015) SwaI (4023) NotI (4031) 4001 TCATGGCTAGTTAATTAACATTTAAATC AGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACA 4101 TACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA

SdaI (3268)

BspLU11I (3281)

Fast-Media
4.<9A,@0,-60 70/4, 19< =060.>498 ,8/ :<9:,2,>498 91 E. coli ><,8=19<7,8>=
C,>,692 # 1,=-BB-6, 1,=-BB-=, 1,=-BB-B2,6

F9< <0=0,<.3 ?=0 986C

(0<=498 # 10G07-

c$#(e#(': E. coli Fa'(-Med a+ ,<0 :<0:,<0/ ,= 48/4@4/?,6 =0,60/ :9?.30= .98>,48482 >30 80.0==,<C ,79?8> 91 :9A/0< 19< :<0:,<,>498 91 200 76 91 =060.>4@0 64;?4/ 9< ,2,< 70/4?7. 30 :9?.30= ,<0 =?::640/ 19< 0,.3 9</0< 91 &B 9< A2,< ,8/ 20 :9?.30= ,<0 =?::640/ 19< 0,.3 9</0< 91 *G,6 A2,<. S($&age a#d '(ab ! (*: Fa'(-Med aF ,<0 =34::0/ ,> <997 >07:0<,>?<0, ,8/ 7?=> -0 =>9<0/ 48 , /<C ,8/ .996 :6,.0. &30C ,<0 =>,-60 19< 2 C0,<= ,> <997 >07:0<,>?<0. )308 :<9:0<6C :<0:,<0/, Fa'(-Med aF :6,>0= 9< -<9>3= ,<0 =>,-60 19< 4 A005= ,> 4IC, ,8/ <07,48 =>0<460 ,8/ =060.>4@0. Q)a! (* c$#(&$!: &30 3423 ;?,64>C ,8/ :0<19<7,8.0 91 0,.3 19<7?6,>498 3,= -008 >0=>0/ A4>3 =970 A4/06C ?=0/ ,8/ :<9:<40>,<C E. coli K12 /0<4@0/ C1061, *L1 -6?0, =><,48= *. &30=0 48.6?/0 DH5 a , &9:10, J 109, &B1, G&100, G&110, G&115, G&116. &30 ,/0;?,>0 :6,=74/= .,<<C482 >30 ,::<9:<4,>0 E. coli <0=4=>,8.0 2080= ,<0 ?=0/ ,= :9=4>4@0 .98><96.
*E. coli <0.4:408> =><,48= .,<<C482 >30 &85 ><,8=:9=98 ,<0 <0=4=>,8> >9 K,8,7C.48 ,8/ +09.48G.

product inForMation

E. coli Fa'(-Med a+ ,<0 ,@,46,-60 A4>3 , 6,<20 @,<40>C 91 :<95,<C9>4. =060.>4@0 ,208>= 48.6?/482 A7:4.46648, B6,=>4.4/48 %, HC2<97C.48 B, K,8,7C.48, #?<97C.48 ,8/ +09.48, (=00 >,-60 -069A). Fa'(-Med a+ 4= ,6=9 ,@,46,-60 A4>3 89 =060.>4@0 ,208> (B,=0) >3,> .,8 -0 :<0:,<0/ A4>3 9< A4>39?> ,8>4-49>4.=. B,=0 A7:4.46648 B6,=>4.4/48 HC2<97C.48 K,8,7C.48 #?<97C.48 +09.48, A2,< H H H H H H H *-G,6 H H H H H &B H H H H H H H

Special handling
C,?>498 =39?6/ -0 0B0<.4=0/ /?<482 3,8/6482 91 F,=>- 0/4,F /?0 >9 :9>08>4,6 ,660<2084. :<9:0<>40= 91 ,8>4-49>4.=. )0,< :<9>0.>4@0 269@0=, /9 89> -<0,>3 >30 /?=>.

Method
F9< .?=>970< .98@08408.0, :<9.0/?<0 4= /4<0.>6C :<48>0/ 98 0,.3 :9?.3. 1- #9?< >30 :9?.3 .98>08>= 48>9 , .60,8 -9<9=464.,>0 26,== -9>>60 9< 16,=5. 2- A// 200 76 91 /4=>4660/ 9< /04984D0/ A,>0<. 3- 4B >39<9?236C -C =A4<6482 >30 26,== -9>>60 9< 16,=5. 4- H0,> 48 , 74.<9A,@0 9@08 98 EDI' :9A0< =0>>482 (,-9?> 450)) ?8>46 -?--60= =>,<> >9 ,::0,< (,-9?> 3 748?>0=). d$ #$( hea( # a c!$'ed c$#(a #e&. 5- %A4<6 208>6C >9 74B >30 :<0:,<,>498 ,8/ <0-30,> 19< 30 =0.98/=. %A4<6 208>6C ,2,48. 6- $0:0,> =>0: 4 41 80.0==,<C ?8>46 >30 70/4?7 4= .97:60>06C /4==96@0/. D9 89> 9@0<-946. 7- A669A >30 70/4?7 >9 .996 >9 50-55 EC, ?=0 /4<0.>6C 19< 64;?4/ 70/4?7, 9< :9?< :6,>0= 19< =964/ 70/4?7. Caution: An solution heated in a microwave oven ma become superheated and suddenl boil when moved or touched. Handle with extreme care. Wear heat-proof gloves. Note: Do not repeat this above procedure once the medium is prepared because the antibiotic will be adversel affected. F$& %&e%a&a( $# $f ')%%!e"e#(ed Fa'(-Med aF Ba'e. - F9669A >30 48=><?.>498= ,-9@0 ,8/ A308 70/4, 3,= .9960/ >9 50-55 IC ,// >30 ,8>4-49>4. ,> >30 ,::<9:<4,>0 .98.08><,>498 19< =060.>498 91 E. coli.

E. coli Fa'(-Med aF ,<0 74.<9A,@0,-60 <0,/C->9-?=0 =964/ 9< 64;?4/ 70/4,, =?::640/ A4>3 , =060.>4@0 ,8>4-49>4., ,8/ .3<9792084. =?-=><,>0= (19< 14@0 <010<08.0=), >30<019<0 /0=4280/ 19< >30 2<9A>3 9< =060.>498 91 E. coli ><,8=19<7,8> .969840=, ,= A066 ,= /0>0.>498 91 -6?0/A34>0 .969840=. - Fa'(-Med aF aga& 19<7?6,>498 4= LB -,=0/ ,2,< 70/4?7 =?::60708>0/ A4>3 =060.>4@0 ,8>4-49>4., 4> 4= ?=0/ 19< =060.>498 91 <0=4=>,8> E. coli .969840= ,1>0< ><,8=19<7,>498 -C @0.>9<= .,<<C482 , =060.>498 <0=4=>,8.0 2080. - Fa'(-Med aF X-ga! 19<7?6,>498 4= , LB -,=0/ ,2,< 70/4?7 =?::60708>0/ A4>3 =060.>4@0 ,8>4-49>4., *-G,6 ,8/ I#&G. I> 4= ?=0/ 19< /0>0.>498 91 -6?0/A34>0 <0=4=>,8> .969840= ,1>0< ><,8=19<7,>498 -C , @0.>9< .,<<C482 LacZ 2080. - Fa'(-Med aF tB 19<7?6,>498 4= , &0<<414. B<9>3 -,=0/ 64;?4/ 70/4?7 =?::60708>0/ A4>3 =060.>4@0 ,8>4-49>4.. I>'= ?=0/ 19< 3423 .066 /08=4>C .?6>?<0 91 ><,8=19<70/ -,.>0<4,, ,8/ 0B><,.>498 91 3423 ;?,8>4>C ,8/ ;?,64>C 91 <0;?4<0/ :6,=74/. E. coli Fa'(-Med a+ 9110< <0=0,<.30<= , ;?4.5 ,8/ .98@08408> A,C >9 :<0:,<0 200 76 91 64;?4/ .?6>?<0 70/4?7, 9< 8-10 ,2,< :6,>0= 48 ,-9?> 14@0 748?>0= '%I!G A IC$")A(E I!%&EAD "F A! A'&"CLA(E.

general product uSe

FaSt-Media+ FeatureS

TECHNICAL SUPPORT Toll free (US): 888-457-5873 Outside US: (+1) 858-457-5873 Europe: +33 562-71-69-39 E-mail: info@invivogen.com Website: www.invivogen.com

3950 Sorrento Valley Blvd. Suite 100 San Diego, CA 92121 - USA